GOALS OF WORK: To review the literature and develop a conceptual framework about prognostic factors for people presenting to medical oncologists with recently diagnosed incurable cancer. MATERIALS AND METHODS: Medline was searched from January 2000 to October 2003 to identify articles testing associations between clinical or laboratory variables and survival time in adults with advanced solid tumours and median survival of 3 to 24 months. We recorded how frequently prognostic factors were significantly associated with survival in univariable and multivariable analyses. RESULTS: There were 53 studies included. The factors associated with survival were organised into four categories related to attributes of the host the tumour, the treatment and the interactions between host, tumour and treatment (symptoms, quality of life, performance status and laboratory tests). Co-morbidity was consistently associated with shorter survival. Age and gender were not consistently associated with survival duration, except in lung cancer where females survived longer. Tumour-related factors associated with shorter survival included primary tumour (lung), metastatic site (liver, brain and visceral) and disease extent. Symptoms associated with shorter survival included those of the anorexia-cachexia syndrome, dyspnoea, pain and impaired physical well being. Performance status was strongly associated with survival in most studies. Laboratory tests associated with shorter survival included anaemia, thrombocytopenia, hypoalbuminaemia and elevated serum levels of both alkaline phosphatase and lactate dehydrogenase. CONCLUSION: Prognostic factors in patients with advanced cancer can be conceptualised as attributes of the host, tumour, treatment and interactions between the three reflected in symptoms, quality of life performance status and laboratory tests.
GOALS OF WORK: To review the literature and develop a conceptual framework about prognostic factors for people presenting to medical oncologists with recently diagnosed incurable cancer. MATERIALS AND METHODS: Medline was searched from January 2000 to October 2003 to identify articles testing associations between clinical or laboratory variables and survival time in adults with advanced solid tumours and median survival of 3 to 24 months. We recorded how frequently prognostic factors were significantly associated with survival in univariable and multivariable analyses. RESULTS: There were 53 studies included. The factors associated with survival were organised into four categories related to attributes of the host the tumour, the treatment and the interactions between host, tumour and treatment (symptoms, quality of life, performance status and laboratory tests). Co-morbidity was consistently associated with shorter survival. Age and gender were not consistently associated with survival duration, except in lung cancer where females survived longer. Tumour-related factors associated with shorter survival included primary tumour (lung), metastatic site (liver, brain and visceral) and disease extent. Symptoms associated with shorter survival included those of the anorexia-cachexia syndrome, dyspnoea, pain and impaired physical well being. Performance status was strongly associated with survival in most studies. Laboratory tests associated with shorter survival included anaemia, thrombocytopenia, hypoalbuminaemia and elevated serum levels of both alkaline phosphatase and lactate dehydrogenase. CONCLUSION: Prognostic factors in patients with advanced cancer can be conceptualised as attributes of the host, tumour, treatment and interactions between the three reflected in symptoms, quality of life performance status and laboratory tests.
Authors: C H Köhne; D Cunningham; F Di Costanzo; B Glimelius; G Blijham; E Aranda; W Scheithauer; P Rougier; M Palmer; J Wils; B Baron; F Pignatti; P Schöffski; S Micheel; H Hecker Journal: Ann Oncol Date: 2002-02 Impact factor: 32.976
Authors: M Pirovano; M Maltoni; O Nanni; M Marinari; M Indelli; G Zaninetta; V Petrella; S Barni; E Zecca; E Scarpi; R Labianca; D Amadori; G Luporini Journal: J Pain Symptom Manage Date: 1999-04 Impact factor: 3.612
Authors: Cristian Massacesi; Barbara Pistilli; Michele Valeri; Paolo Lippe; Marco B L Rocchi; Riccardo Cellerino; Andrea Piga Journal: Am J Clin Oncol Date: 2002-04 Impact factor: 2.339
Authors: Edward Chow; KinWah Fung; Tony Panzarella; Andrea Bezjak; Cyril Danjoux; Ian Tannock Journal: Int J Radiat Oncol Biol Phys Date: 2002-08-01 Impact factor: 7.038
Authors: Aja S McCutchen; Juan Carlos Munoz; Lacie Brenner; Peter Wludyka; Kenneth J Vega Journal: Int J Colorectal Dis Date: 2011-01-27 Impact factor: 2.571
Authors: M Frigeri; S De Dosso; O Castillo-Fernandez; K Feuerlein; H Neuenschwander; P Saletti Journal: Support Care Cancer Date: 2012-06-01 Impact factor: 3.603
Authors: Megan E Rosa-Caldwell; Jacob L Brown; David E Lee; Michael P Wiggs; Richard A Perry; Wesley S Haynie; Aaron R Caldwell; Tyrone A Washington; Wen-Juo Lo; Nicholas P Greene Journal: Appl Physiol Nutr Metab Date: 2019-10-16 Impact factor: 2.665
Authors: Jan Olofson; Catharina Dellborg; Marianne Sullivan; Bengt Midgren; Oscar Caro; Bengt Bergman Journal: Qual Life Res Date: 2009-02-14 Impact factor: 4.147